Loading…

Effects of chronic nitric oxide synthase inhibition on V'O^sub 2max^ and exercise capacity in mice

Acute inhibition of NOS by L-NAME (N[omega]-nitro-L-arginine methyl ester) is known to decrease maximal oxygen consumption (V'O2max) and impair maximal exercise capacity, whereas the effects of chronic L-NAME treatment on V'O2max and exercise performance have not been studied so far. In th...

Full description

Saved in:
Bibliographic Details
Published in:Naunyn-Schmiedeberg's archives of pharmacology 2017-03, Vol.390 (3), p.235
Main Authors: Wojewoda, M, Przyborowski, K, Sitek, B, Zakrzewska, A, Mateuszuk, L, Zoladz, J A, Chlopicki, S
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 3
container_start_page 235
container_title Naunyn-Schmiedeberg's archives of pharmacology
container_volume 390
creator Wojewoda, M
Przyborowski, K
Sitek, B
Zakrzewska, A
Mateuszuk, L
Zoladz, J A
Chlopicki, S
description Acute inhibition of NOS by L-NAME (N[omega]-nitro-L-arginine methyl ester) is known to decrease maximal oxygen consumption (V'O2max) and impair maximal exercise capacity, whereas the effects of chronic L-NAME treatment on V'O2max and exercise performance have not been studied so far. In this study, we analysed the effect of L-NAME treatment, (LN2 and LN12, respectively) on V'O2max and exercise capacity (in maximal incremental running and prolonged sub-maximal incremental running tests), systemic NO bioavailability (plasma nitrite (NO2 -) and nitrate (NO3 -)) and prostacyclin (PGI2) production in C57BL6/J mice. Mice treated with L-NAME for 2 weeks (LN2) displayed higher V'O2max and better running capacity than age-matched control mice. In LN2 mice, NO bioavailability was preserved, as evidenced by maintained NO2 - plasma concentration. PGI2 production was activated (increased 6-keto-PGF1[alpha] plasma concentration) and the number of circulating erythrocytes (RBC) and haemoglobin concentration were increased. In mice treated with L-NAME for 12 weeks (LN12), NO bioavailability was decreased (lower NO2 - plasma concentration), and 6-keto-PGF1[alpha] plasma concentration and RBC number were not elevated compared to age-matched control mice. However, LN12 mice still performed better during the maximal incremental running test despite having lower V'O2max. Interestingly, the LN12 mice showed poorer running capacity during the prolonged sub-maximal incremental running test. To conclude, short-term (2 weeks) but not long-term (12 weeks) treatment with L-NAME activated robust compensatory mechanisms involving preservation of NO2- plasma concentration, overproduction of PGI2 and increased number of RBCs, which might explain the fully preserved exercise capacity despite the inhibition of NOS.
doi_str_mv 10.1007/s00210-016-1318-3
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1867560623</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4313254681</sourcerecordid><originalsourceid>FETCH-proquest_journals_18675606233</originalsourceid><addsrcrecordid>eNqNi8FKAzEURYMoOLZ-gLsHLlxF30ucdLqWirtuxGVLJs0wr9ikJhmY_r1Z-AHChbM45wrxQPhMiKuXjKgIJZKRpKmT-ko09KqVpDWpa9FU3UlS6-5W3OV8RERDbduIfjMM3pUMcQA3phjYQeCSKuLMBw_5EsposwcOI_dcOAao-3ra7vLUgzrZeQc2HMDPPjmuobNn67hc6gNO7PxS3Az2O_v7Py7E4_vm8-1DnlP8mXwu-2OcUqhqT51ZtQaN0vp_1S9E4EuG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1867560623</pqid></control><display><type>article</type><title>Effects of chronic nitric oxide synthase inhibition on V'O^sub 2max^ and exercise capacity in mice</title><source>Springer Link</source><creator>Wojewoda, M ; Przyborowski, K ; Sitek, B ; Zakrzewska, A ; Mateuszuk, L ; Zoladz, J A ; Chlopicki, S</creator><creatorcontrib>Wojewoda, M ; Przyborowski, K ; Sitek, B ; Zakrzewska, A ; Mateuszuk, L ; Zoladz, J A ; Chlopicki, S</creatorcontrib><description>Acute inhibition of NOS by L-NAME (N[omega]-nitro-L-arginine methyl ester) is known to decrease maximal oxygen consumption (V'O2max) and impair maximal exercise capacity, whereas the effects of chronic L-NAME treatment on V'O2max and exercise performance have not been studied so far. In this study, we analysed the effect of L-NAME treatment, (LN2 and LN12, respectively) on V'O2max and exercise capacity (in maximal incremental running and prolonged sub-maximal incremental running tests), systemic NO bioavailability (plasma nitrite (NO2 -) and nitrate (NO3 -)) and prostacyclin (PGI2) production in C57BL6/J mice. Mice treated with L-NAME for 2 weeks (LN2) displayed higher V'O2max and better running capacity than age-matched control mice. In LN2 mice, NO bioavailability was preserved, as evidenced by maintained NO2 - plasma concentration. PGI2 production was activated (increased 6-keto-PGF1[alpha] plasma concentration) and the number of circulating erythrocytes (RBC) and haemoglobin concentration were increased. In mice treated with L-NAME for 12 weeks (LN12), NO bioavailability was decreased (lower NO2 - plasma concentration), and 6-keto-PGF1[alpha] plasma concentration and RBC number were not elevated compared to age-matched control mice. However, LN12 mice still performed better during the maximal incremental running test despite having lower V'O2max. Interestingly, the LN12 mice showed poorer running capacity during the prolonged sub-maximal incremental running test. To conclude, short-term (2 weeks) but not long-term (12 weeks) treatment with L-NAME activated robust compensatory mechanisms involving preservation of NO2- plasma concentration, overproduction of PGI2 and increased number of RBCs, which might explain the fully preserved exercise capacity despite the inhibition of NOS.</description><identifier>ISSN: 0028-1298</identifier><identifier>EISSN: 1432-1912</identifier><identifier>DOI: 10.1007/s00210-016-1318-3</identifier><language>eng</language><publisher>Heidelberg: Springer Nature B.V</publisher><ispartof>Naunyn-Schmiedeberg's archives of pharmacology, 2017-03, Vol.390 (3), p.235</ispartof><rights>Naunyn-Schmiedeberg's Archives of Pharmacology is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Wojewoda, M</creatorcontrib><creatorcontrib>Przyborowski, K</creatorcontrib><creatorcontrib>Sitek, B</creatorcontrib><creatorcontrib>Zakrzewska, A</creatorcontrib><creatorcontrib>Mateuszuk, L</creatorcontrib><creatorcontrib>Zoladz, J A</creatorcontrib><creatorcontrib>Chlopicki, S</creatorcontrib><title>Effects of chronic nitric oxide synthase inhibition on V'O^sub 2max^ and exercise capacity in mice</title><title>Naunyn-Schmiedeberg's archives of pharmacology</title><description>Acute inhibition of NOS by L-NAME (N[omega]-nitro-L-arginine methyl ester) is known to decrease maximal oxygen consumption (V'O2max) and impair maximal exercise capacity, whereas the effects of chronic L-NAME treatment on V'O2max and exercise performance have not been studied so far. In this study, we analysed the effect of L-NAME treatment, (LN2 and LN12, respectively) on V'O2max and exercise capacity (in maximal incremental running and prolonged sub-maximal incremental running tests), systemic NO bioavailability (plasma nitrite (NO2 -) and nitrate (NO3 -)) and prostacyclin (PGI2) production in C57BL6/J mice. Mice treated with L-NAME for 2 weeks (LN2) displayed higher V'O2max and better running capacity than age-matched control mice. In LN2 mice, NO bioavailability was preserved, as evidenced by maintained NO2 - plasma concentration. PGI2 production was activated (increased 6-keto-PGF1[alpha] plasma concentration) and the number of circulating erythrocytes (RBC) and haemoglobin concentration were increased. In mice treated with L-NAME for 12 weeks (LN12), NO bioavailability was decreased (lower NO2 - plasma concentration), and 6-keto-PGF1[alpha] plasma concentration and RBC number were not elevated compared to age-matched control mice. However, LN12 mice still performed better during the maximal incremental running test despite having lower V'O2max. Interestingly, the LN12 mice showed poorer running capacity during the prolonged sub-maximal incremental running test. To conclude, short-term (2 weeks) but not long-term (12 weeks) treatment with L-NAME activated robust compensatory mechanisms involving preservation of NO2- plasma concentration, overproduction of PGI2 and increased number of RBCs, which might explain the fully preserved exercise capacity despite the inhibition of NOS.</description><issn>0028-1298</issn><issn>1432-1912</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqNi8FKAzEURYMoOLZ-gLsHLlxF30ucdLqWirtuxGVLJs0wr9ikJhmY_r1Z-AHChbM45wrxQPhMiKuXjKgIJZKRpKmT-ko09KqVpDWpa9FU3UlS6-5W3OV8RERDbduIfjMM3pUMcQA3phjYQeCSKuLMBw_5EsposwcOI_dcOAao-3ra7vLUgzrZeQc2HMDPPjmuobNn67hc6gNO7PxS3Az2O_v7Py7E4_vm8-1DnlP8mXwu-2OcUqhqT51ZtQaN0vp_1S9E4EuG</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Wojewoda, M</creator><creator>Przyborowski, K</creator><creator>Sitek, B</creator><creator>Zakrzewska, A</creator><creator>Mateuszuk, L</creator><creator>Zoladz, J A</creator><creator>Chlopicki, S</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20170301</creationdate><title>Effects of chronic nitric oxide synthase inhibition on V'O^sub 2max^ and exercise capacity in mice</title><author>Wojewoda, M ; Przyborowski, K ; Sitek, B ; Zakrzewska, A ; Mateuszuk, L ; Zoladz, J A ; Chlopicki, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_18675606233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wojewoda, M</creatorcontrib><creatorcontrib>Przyborowski, K</creatorcontrib><creatorcontrib>Sitek, B</creatorcontrib><creatorcontrib>Zakrzewska, A</creatorcontrib><creatorcontrib>Mateuszuk, L</creatorcontrib><creatorcontrib>Zoladz, J A</creatorcontrib><creatorcontrib>Chlopicki, S</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Naunyn-Schmiedeberg's archives of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wojewoda, M</au><au>Przyborowski, K</au><au>Sitek, B</au><au>Zakrzewska, A</au><au>Mateuszuk, L</au><au>Zoladz, J A</au><au>Chlopicki, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of chronic nitric oxide synthase inhibition on V'O^sub 2max^ and exercise capacity in mice</atitle><jtitle>Naunyn-Schmiedeberg's archives of pharmacology</jtitle><date>2017-03-01</date><risdate>2017</risdate><volume>390</volume><issue>3</issue><spage>235</spage><pages>235-</pages><issn>0028-1298</issn><eissn>1432-1912</eissn><abstract>Acute inhibition of NOS by L-NAME (N[omega]-nitro-L-arginine methyl ester) is known to decrease maximal oxygen consumption (V'O2max) and impair maximal exercise capacity, whereas the effects of chronic L-NAME treatment on V'O2max and exercise performance have not been studied so far. In this study, we analysed the effect of L-NAME treatment, (LN2 and LN12, respectively) on V'O2max and exercise capacity (in maximal incremental running and prolonged sub-maximal incremental running tests), systemic NO bioavailability (plasma nitrite (NO2 -) and nitrate (NO3 -)) and prostacyclin (PGI2) production in C57BL6/J mice. Mice treated with L-NAME for 2 weeks (LN2) displayed higher V'O2max and better running capacity than age-matched control mice. In LN2 mice, NO bioavailability was preserved, as evidenced by maintained NO2 - plasma concentration. PGI2 production was activated (increased 6-keto-PGF1[alpha] plasma concentration) and the number of circulating erythrocytes (RBC) and haemoglobin concentration were increased. In mice treated with L-NAME for 12 weeks (LN12), NO bioavailability was decreased (lower NO2 - plasma concentration), and 6-keto-PGF1[alpha] plasma concentration and RBC number were not elevated compared to age-matched control mice. However, LN12 mice still performed better during the maximal incremental running test despite having lower V'O2max. Interestingly, the LN12 mice showed poorer running capacity during the prolonged sub-maximal incremental running test. To conclude, short-term (2 weeks) but not long-term (12 weeks) treatment with L-NAME activated robust compensatory mechanisms involving preservation of NO2- plasma concentration, overproduction of PGI2 and increased number of RBCs, which might explain the fully preserved exercise capacity despite the inhibition of NOS.</abstract><cop>Heidelberg</cop><pub>Springer Nature B.V</pub><doi>10.1007/s00210-016-1318-3</doi></addata></record>
fulltext fulltext
identifier ISSN: 0028-1298
ispartof Naunyn-Schmiedeberg's archives of pharmacology, 2017-03, Vol.390 (3), p.235
issn 0028-1298
1432-1912
language eng
recordid cdi_proquest_journals_1867560623
source Springer Link
title Effects of chronic nitric oxide synthase inhibition on V'O^sub 2max^ and exercise capacity in mice
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T13%3A44%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20chronic%20nitric%20oxide%20synthase%20inhibition%20on%20V'O%5Esub%202max%5E%20and%20exercise%20capacity%20in%20mice&rft.jtitle=Naunyn-Schmiedeberg's%20archives%20of%20pharmacology&rft.au=Wojewoda,%20M&rft.date=2017-03-01&rft.volume=390&rft.issue=3&rft.spage=235&rft.pages=235-&rft.issn=0028-1298&rft.eissn=1432-1912&rft_id=info:doi/10.1007/s00210-016-1318-3&rft_dat=%3Cproquest%3E4313254681%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_18675606233%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1867560623&rft_id=info:pmid/&rfr_iscdi=true